scholarly journals Effects of Blended (Yellow) vs Forced Coagulation (Blue) Currents on Adverse Events, Complete Resection, or Polyp Recurrence After Polypectomy in a Large Randomized Trial

2020 ◽  
Vol 159 (1) ◽  
pp. 119-128.e2 ◽  
Author(s):  
Heiko Pohl ◽  
Ian S. Grimm ◽  
Matthew T. Moyer ◽  
Muhammad K. Hasan ◽  
Douglas Pleskow ◽  
...  
Keyword(s):  
Adverse Events ◽  
Randomized Trial ◽  
Complete Resection ◽  
Polyp Recurrence ◽  
Large Randomized Trial

scholarly journals Stereotactic radiosurgery for treating meningiomas eligible for complete resection

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Maximilian I. Ruge ◽  
Juman Tutunji ◽  
Daniel Rueß ◽  
Eren Celik ◽  
Christian Baues ◽  
...  
Keyword(s):  
Adverse Events ◽  
Stereotactic Radiosurgery ◽  
Medical Condition ◽  
Local Tumor Control ◽  
Complete Resection ◽  
Neurological Deficits ◽  
Tumor Control ◽  
Recurrence Rates ◽  
Treatment Volume

Abstract Background For meningiomas, complete resection is recommended as first-line treatment while stereotactic radiosurgery (SRS) is established for meningiomas of smaller size considered inoperable. If the patient´s medical condition or preference excludes surgery, SRS remains a treatment option. We evaluated the efficacy and safety of SRS in a cohort comprising these cases. Methods In this retrospective single-centre analysis we included patients receiving single fraction SRS either by modified LINAC or robotic guidance by Cyberknife for potentially resectable intracranial meningiomas. Treatment-related adverse events as well as local and regional control rates were determined from follow-up imaging and estimated by the Kaplan–Meier method. Results We analyzed 188 patients with 218 meningiomas. The median radiological, and clinical follow-up periods were 51.4 (6.2–289.6) and 55.8 (6.2–300.9) months. The median tumor volume was 4.2 ml (0.1–22), and the mean marginal radiation dose was 13.0 ± 3.1 Gy, with reference to the 80.0 ± 11.2% isodose level. Local recurrence was observed in one case (0.5%) after 239 months. The estimated 2-, 5-, 10- and 15-year regional recurrence rates were 1.5%, 3.0%, 6.6% and 6.6%, respectively. Early adverse events (≤ 6 months after SRS) occurred in 11.2% (CTCEA grade 1–2) and resolved during follow-up in 7.4% of patients, while late adverse events were documented in 14.4% (grade 1–2; one case grade 3). Adverse effects (early and late) were associated with the presence of symptoms or neurological deficits prior to SRS (p < 0.03) and correlated with the treatment volume (p < 0.02). Conclusion In this analysis SRS appears to be an effective treatment for patients with meningiomas eligible for complete resection and provides reliable long-term local tumor control with low rates of mild morbidity.

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified

2009 ◽  
Vol 62 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Liz Down ◽  
Chris Metcalfe ◽  
Kerry Avery ◽  
Sian Noble ◽  
J. Athene Lane ◽  
...  
Keyword(s):  
Randomized Trial ◽  
General Practitioners ◽  
Large Randomized Trial

scholarly journals Effects of prolonged and exclusive breastfeeding on child height, weight, adiposity, and blood pressure at age 6.5 y: evidence from a large randomized trial

2007 ◽  
Vol 86 (6) ◽  
pp. 1717-1721 ◽  
Author(s):  
Michael S Kramer ◽  
Lidia Matush ◽  
Irina Vanilovich ◽  
Robert W Platt ◽  
Natalia Bogdanovich ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Randomized Trial ◽  
Exclusive Breastfeeding ◽  
Child Height ◽  
Large Randomized Trial

scholarly journals Achieving blood pressure control targets in hypertensive patients of rural China – A pilot randomized trial

2020 ◽  
Author(s):  
Xiao Huang ◽  
Lishun Liu ◽  
Yun Song ◽  
Lan Gao ◽  
Min Zhao ◽  
...  
Keyword(s):  
Adverse Events ◽  
Randomized Trial ◽  
Real World ◽  
Large Scale ◽  
Rural China ◽  
Standard Group ◽  
Open Label ◽  
Target Groups ◽  
Serious Adverse Events ◽  
Hypertensive Patients

Abstract Background This study aimed to test the feasibility and titration methods to achieve specific BP control targets in hypertensive patients of rural China. Methods A randomized, controlled, open-label trial was conducted in Rongcheng, China. We enrolled 105 hypertensive participants aged over 60 years, and who had no history of stroke and cardiovascular disease. The patients were randomly assigned to one of three systolic BP target groups: standard: 140 - < 150mmHg; moderately intensive: 130 - < 140mmHg; and intensive: <130mmHg. Patients were followed for 6 months. Discussion The optimal target for SBP lowering is still uncertain worldwide and such information is critically needed, especially in China. However, in China the rates of awareness, treatment and control are only 46.9%, 40.7% and 15.3%, respectively. It is challenging to achieve BP control in the real world and it is very important to develop population-specific BP control protocols that fully consider the population’s characteristics, such as age, sex, socio-economic status, compliance, education level and lifestyle. This randomized trial showed feasibility and safety of the titration protocol to achieve desirable SBP targets (<150, <140, and <130mmHg) in a sample of rural Chinese hypertensive patients. The three BP target groups had similar baseline characteristics. After 6 months of treatment, the mean SBP measured at an office visit was 137.2mmHg, 131.1mmHg, and 124.2mmHg in the three groups. Home BP and central aortic BP measurements were also obtained. At 6 months, home BP measurements (2 hours after drug administration) showed a mean SBP of 130.9 mmHg in the standard group, 124.9 mmHg in the moderately intense group, and 119.7 mmHg in the intensive group. No serious adverse events were recorded over the 6-month study period. Rates of adverse events including dry cough, palpitations, and arthralgia were low and showed no significant differences between the three groups. This trial gained real world experience and laid the foundation for a future large-scale BP target study.

scholarly journals Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults

2010 ◽  
Vol 17 (4) ◽  
pp. 537-544 ◽  
Author(s):  
Roberto Gasparini ◽  
Michele Conversano ◽  
Gianni Bona ◽  
Giovanni Gabutti ◽  
Alessandra Anemona ◽  
...  
Keyword(s):  
Young Adults ◽  
Adverse Events ◽  
Randomized Trial ◽  
Conjugate Vaccine ◽  
Antibody Responses ◽  
Adolescents And Young Adults ◽  
Tdap Vaccine ◽  
Glycoconjugate Vaccine ◽  
Clinically Significant ◽  
Quadrivalent Meningococcal Conjugate Vaccine

ABSTRACT This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received either MenACWY-CRM and Tdap, MenACWY-CRM and saline placebo, or Tdap and saline placebo. No significant increase in reactogenicity and no clinically significant vaccine-related adverse events (AEs) occurred when MenACWY-CRM and Tdap were administered concomitantly. Similar immunogenic responses to diphtheria, tetanus, and meningococcal (serogroups A, C, W-135, and Y) antigens were observed, regardless of concomitant vaccine administration. Antipertussis antibody responses were comparable between vaccine groups for filamentous hemagglutinin and were slightly lower, although not clinically significantly, for pertussis toxoid and pertactin when the two vaccines were administered concomitantly. These results indicate that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic and that it can be coadministered with Tdap to adolescents and young adults.

Which Catheter is the Best Buy?

1995 ◽  
Vol 15 (4) ◽  
pp. 303-304 ◽  
Author(s):  
Beth Piraino
Keyword(s):  
Randomized Trial ◽  
Tenckhoff Catheter ◽  
Comparative Cost ◽  
Large Randomized Trial ◽  
Convincing Data

Good but not perfect results can be obtained with many types of catheters. Convincing data demonstrating superiority of one catheter over another are not available. What is the comparative cost of these catheters? The straight Tenckhoff catheter remains the least expensive at $42.50 (Quinton Instrument Company). Until a large randomized trial is done demonstrating a clear superiority of another catheter, we will continue to use the straight double-cuff Tenckhoff catheter.

Sign in / Sign up

Export Citation Format

Share Document